Budesonide Yields Durable Reduction in eGFR for IgA Nephropathy
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 21, 2023 -- For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR) than placebo, which lasts for two years, according to a study published online Aug. 14 in The Lancet.
Richard Lafayette, M.D., from Stanford University in California, and colleagues conducted a phase 3, multicenter, randomized trial involving adults with primary IgA nephropathy, eGFR of 35 to 90 mL/min/1.73 m2, and persistent proteinuria despite optimized renin-angiotensin system blockade. Patients were randomly assigned to receive 16 mg/day budesonide or matching placebo (182 per treatment group) for nine months followed by a 15-month observational follow-up period.
The researchers found that over two years, the time-weighted average of eGFR showed a significant treatment benefit with budesonide versus placebo (difference, 5.05 mL/min/1.73 m2), with time-weighted average changes of −2.47 and −7.52 mL/minute/1.73 m2 reported with budesonide and placebo, respectively. During treatment with budesonide, the most commonly reported treatment-emergent adverse events were peripheral edema, hypertension, muscle spasms, acne, and headache. There were no reports of treatment-related deaths.
"The final NefIgArd study analysis has verified the clinical benefit of Nefecon treatment as the first approved, disease-specific treatment that is able to significantly reduce the rate of kidney function decline in patients with primary IgA nephropathy," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Calliditas Therapeutics, which manufactures Nefecon and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Men Face More Diabetes Complications Than Women
FRIDAY, May 17, 2024 -- Men with diabetes have a greater risk for complications than women, irrespective of diabetes duration, according to a study published online May 16 in...
Negative Link Seen for Oxidative Balance Score With Chronic Kidney Disease
FRIDAY, May 17, 2024 -- There is a negative association for oxidative balance score (OBS) with chronic kidney disease, according to a study published online April 23 in Frontiers...
Cardiovascular, Kidney, and Metabolic Syndrome Highly Prevalent in the U.S.
FRIDAY, May 10, 2024 -- Cardiovascular, kidney, and metabolic (CKM) syndrome is highly prevalent in the United States, with more than 90 percent of adults meeting the criteria for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.